-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Diffuse large B-cell lymphoma (DLBCL) is one of the most invasive subtypes of non-Hodgkin’s lymphoma (NHL), accounting for 30-40% of NHL patients.
Diffuse large B-cell lymphoma (DLBCL) is one of the most invasive subtypes of non-Hodgkin’s lymphoma (NHL), accounting for 30-40% of NHL patients.
A total of 332 newly diagnosed DLBCL patients were recruited for this study .
diagnosis
Among these patients, 92.
This study confirmed that the bioavailability level of 25(OH)D can be used as a new prognostic biomarker for DLBCL patients.
This study confirmed that the bioavailability level of 25(OH)D can be used as a new prognostic biomarker for DLBCL patients.
Original source:
Peizhan Chen.
Bioavailable 25(OH)D level is associated with clinical outcomes of patients with diffuse large B-cell lymphoma: An exploratory study.
Leave a message here